3Curran S,Murray GI.Matrix metalloproteinases:molecular aspects of their roles in tumor invasion and metastasis[J].Eur J Cancer,2000,36 (13):1621-1630.
4Hornebeck W,Lambert E,Petitfr E,et al.Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression[J].Biochimie,2005,87(3/4):377 -383.
5Nakoman C,Resmi H,Ay O,et al.Effects of basic fibroblast factor (bFGF) on MMP-2,TIMP-2 and type-Ⅰ collagen levels in human lung carcinoma fibroblasts[J].Biochimie,2005,87 (3-4):343-351.
7Fang J,Shing Y,Wiederschain D,et al.Matrix metalloproteinase-2 is required for the switch to the angiogenie phenotype in a tumor model[J].Proc Natl Acad Sci USA,2000,97 (8):3884-3889.
1[1]Albrechtsen R, Wewer UM, Liotta LA. Basement membranes in human cancer. Pathol Annu,1986,21(Pt 2)∶251-276.
2[2]Kawamata H, Kameyama S, Kawai K, et al. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer,1995,63(4)∶568-575.
3[4]Urbanski SJ, Edwards DR, Maitland A, et al. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer,1992,66(6)∶1188-1194.
4[5]Hofmann UB, Westphal JR, Van Muijen GN, et al. Matrix metalloproteinases in human melanoma. J Invest Dermatol,2000,115(3)∶337-344.
5[6]Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer Res,2000,20(2B)∶1311-1316.
6Herrera-Gajol A, Jothy S. Adhesion proteins in the biology of breast cancer: contribution of CD44 [J]. Exp Mol Pathol, 1999,66(2) : 149 - 156.
7Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion [J]. Biochem Biophys Acta, 1987,907(3) : 191 - 217.
8Radotra B, Mccormick D. Glioma invasion in vitro is mediated by CD44-hyaluronan interactions [J]. J Pathol, 1997, 181 (4) :434 - 438.
9Saito H, Tsujitani S, Katano K, et al. Serum concertration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma [J]. Cancer, 1998,86(6) : 1094- 1101.
10Charpin C, Garcia S, Bouvier C, et al. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas [J]. Hum Pathol, 1997,28(3) :289 - 296.
4Parkin DM,Bray F,Ferlay J,Pisani P.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
5Youlden DR,Cramb SM,Baade PD.The International Epidemiology of Lung Cancer:geographical distribution and secular trends[J].J Tho-rac Oncol,2008,3(8):819-831.
6Lee E-S,Son D-S,Kim S-H,et al.Prediction of recurrence-free sur-vival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression[J].Clin Cancer Res,2008,14(22):7397-7404.
8Li M,Yamamoto H,Adachi Y,Maruyama Y,Shinomura Y.Role of matrix metalloproteinase-7(matrilysin)in human cancer invasion,apoptosis,growth,and angiogenesis[J].Exp Biol Med,2006,231(1):20-27.
9Zhang D,Lu H,Li J,Shi X,Huang C.Essential roles of ERKs and p38K in up-regulation of GST A1expression by Maotai content in hu-man hepatoma cell line Hep3B[J].Mol Cell Biochem,2006,293(1-2):161-171.
10Sorensen M,Autrup H,Tjonneland A,Overvad K,Raaschou-Nielsen O.Genetic polymorphisms in CYP1B1,GSTA1,NQO1and NAT2and the risk of lung cancer[J].Cancer Lett,2005,221(2):185-190.
